Faeth Therapeutics signs Roche supply deal for breast cancer trial
Faeth will sponsor the Phase 1b/2 study and retain PIKTOR rights, while Roche supplies giredestrant under the collaboration.

A Phase 1b/2 breast-cancer study will test PIKTOR with the experimental hormone therapy giredestrant after Faeth Therapeutics, Inc. NASDAQFTH announced a clinical collaboration on Monday. Interim data from the breast-cancer trial are expected in 2027.
Faeth will sponsor and conduct study FTH-PIK-101 under the agreement with F. Hoffmann-La Roche Ltd. Roche SWXRO SWXROP OTCMKTSRHHBY will supply giredestrant, while Faeth retains all rights to PIKTOR.
Faeth is an Austin-based clinical-stage biotechnology company built around its lead oral cancer regimen, with development programmes in breast and endometrial cancer.
Shares last closed at US$10.03 on Nasdaq at 4:00 p.m. EST on Nov. 13, according to Google Finance NASDAQFTH. That close precedes Monday's announcement and does not measure investors' response.
Faeth Retains Rights And Trial Responsibility
The disclosed obligations leave study sponsorship and conduct with Faeth and drug supply with Roche. The Nov. 16 announcement does not disclose an upfront payment, milestone schedule or cost-sharing formula. It provides no financial terms with which to quantify Roche's development exposure beyond supplying medicine.
The study targets hormone receptor-positive, HER2-negative advanced breast cancer. Faeth says activation of the PI3K/AKT/mTOR signalling pathway is a recognised mechanism of resistance to endocrine therapy, providing the rationale for combining PIKTOR with a hormone-directed treatment.
PIKTOR combines serabelisib, a PI3K-alpha inhibitor, with sapanisertib, an mTORC1/mTORC2 inhibitor. The approach is designed to block several points in the same pathway; its proposed benefit alongside giredestrant remains to be established in patients.
"Endocrine therapy remains the backbone of treatment in HR+/HER2- breast cancer, and resistance driven by the PI3K/AKT/mTOR pathway is one of the central problems in this setting," Faeth chief executive Anand Parikh said in Monday's release.
The breast-cancer trial dosed its first patient in April 2026. Monday's release does not specify a first-dose date for the giredestrant combination, a target enrolment, a control arm or a primary endpoint.
It also reports no clinical safety or efficacy results for that combination and no FDA agreement on a registration-study design. The collaboration therefore supplies an investigational treatment partner while leaving the clinical evidence to be generated.
Read more: Summit Therapeutics reports FDA refusal for lung cancer treatment
Faeth reported US$174.8 million in cash, equivalents and marketable securities at Sept. 30. Its Nov. 3 results put quarterly research and development expenses at US$11.7 million, driven principally by PIKTOR and other programme costs. The financial-results section gives no cash-runway forecast.
An Approved Rival Is Already On The Market
The competitive field includes Celcuity Inc. NASDAQCELC, which said on Nov. 5 that REVTORPYK, or gedatolisib, became commercially available on Sept. 30. It is used with fulvestrant, with or without palbociclib, for eligible patients with advanced HR-positive, HER2-negative disease without a detected PIK3CA mutation. The indication requires disease progression on or after at least one line of endocrine therapy in the metastatic setting.
Celcuity reported coverage in health plans representing 91 per cent of U.S. commercial and Medicare lives. The differing development stages and treatment combinations provide no head-to-head evidence comparing gedatolisib with PIKTOR.
Patient selection also separates programmes in this market. Roche's June 2 regulatory update described a separate giredestrant application with everolimus for ESR1-mutated advanced breast cancer, with an FDA decision expected in December 2026.
Read more: Guardant Health adds five epigenomic tools for cancer treatment selection
Roche's nearer dated milestone is the FDA's Nov. 30 goal for giredestrant in early-stage breast cancer, a separate application from the advanced-disease combination. That decision concerns giredestrant's early-stage use; Faeth's next breast-cancer data milestone remains the interim safety and efficacy update expected in 2027.
Adrian Kessler






